Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The use of protease inhibitors in the treatment of HIV-1 infection is associated with the new onset of diabetes mellitus, hyperlipidaemia and lipodystrophy. It is unclear whether these findings are coincidental or whether they reflect a causative effect of protease inhibitors. OBJECTIVE: To evaluate the effect of treatment with protease inhibitors on insulin sensitivity, oral glucose tolerance and serum lipids in HIV-infected patients in order to determine whether treatment with protease inhibitors can cause peripheral insulin resistance. DESIGN: Cross-sectional controlled study in HIV-infected patients treated with protease inhibitors to assess insulin sensitivity, oral glucose tolerance and changes in serum lipids. METHODS: Sixty-seven patients treated with protease inhibitors, 13 therapy-naive patients and 18 HIV-negative control subjects were tested for insulin sensitivity (intravenous insulin tolerance test). In a subgroup of 24 treated patients, oral glucose tolerance was determined. Serum lipids prior to and under treatment with protease inhibitors were compared. RESULTS: Patients on protease inhibitors had a significantly decreased insulin sensitivity when compared with therapy-naive patients (median, 75 and 156 micromol/l/min, respectively; P < 0.001). All treated patients with impaired (n=4) or diabetic (n=9) oral glucose tolerance, and four out of 11 patients with normal glucose tolerance showed peripheral insulin resistance; all therapy-naive patients had normal insulin sensitivity. Treatment with protease inhibitors led to a significant increase in total triglycerides and cholesterol in the 67 treated patients (median increase, 113 and 37 mg/ml, respectively). CONCLUSION: Treatment with protease inhibitors is associated with peripheral insulin resistance, leading to impaired or diabetic oral glucose tolerance in some of the patients, and with hyperlipidaemia. Overall, there is a large variation in the severity and clinical presentation of protease inhibitor-associated metabolic side-effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other immunosuppressive therapy associated with a lower risk of PTDM include antithymocyte globulin and Interleukin 2 receptor antagonists.1583,1589,1596,1597”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1597]
Citations
Cites
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Carpenter, C. C. J. (1997) · JAMA · doi:10.1001/jama.1997.03540480062040 · Cited by 725
Peng, C., Ho, B. K., Chang, T. W., & Chang, N. T. (1989) · Journal of Virology · doi:10.1128/jvi.63.6.2550-2556.1989 · Cited by 371
Crystalluria and Urinary Tract Abnormalities Associated with Indinavir
Kopp, J. B., Miller, K. D., Mican, J. A. M., Feuerstein, I. M., Vaughan, E., Baker, C., Pannell, L. K., & Falloon, J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-2-199707150-00004 · Cited by 312
McKeigue, P. M., Pierpoint, T., Ferrie, J. E., & Marmot, M. G. (1992) · Diabetologia · doi:10.1007/bf00429101 · Cited by 279
Protease inhibitor-associated hyperglycaemia
Dubé, M. P., Johnson, D. L., Currier, J. S., & Leedom, J. M. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63513-1 · Cited by 241
Benign symmetric lipomatosis associated with protease inhibitors
Hengel, R., Watts, N., & Lennox, J. (1997) · The Lancet · doi:10.1016/s0140-6736(05)64011-1 · Cited by 169
Severe Diabetes Associated with Protease Inhibitor Therapy
Visnegarwala, F., Krause, K. L., & Musher, D. M. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-10-199711150-00016 · Cited by 136
Current Knowledge and Future Prospects for the Use of HIV Protease Inhibitors
Moyle, G. J., & Gazzard, B. (1996) · Drugs · doi:10.2165/00003495-199651050-00001 · Cited by 130
New-Onset Diabetes Mellitus Associated with Use of Protease Inhibitor
Eastone, J. A., & Decker, C. F. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-10-199711150-00017 · Cited by 122
Research works printed but not linked: 2
- McDonald, 1997, Arch Intern Med, 157, 951, 10.1001/archinte.1997.00440300037003 · doi:10.1001/archinte.1997.00440300037003 · Paper page
- 1985, World Health Organ Tech Rep Ser, 727, 10
Cited by
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Friis-Møller, N., Weber, R., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,077
“date [9,10,48,49], comparing levels during PI therapy with either pre-therapy levels or levels in PI-naive HIV-infected patients, were 28% for total cholesterol and 96% for triglycerides.”
ResultAdverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Metadata
- Authors
- Walli, R., Herfort, O., Michl, G. M., Demant, T., Jäger, H., Dieterle, C., Bogner, J. R., Landgraf, R., & Goebel, F. D.
- Affiliations
- LMU Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
- ORCID
- Bogner, Johannes R.
- Venue
- AIDS
- Published
- 1998-10
- Volume
- 12
- Issue
- 15
- Pages
- F167-F173
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2060210361
- Cited by
- 519
- References
- 14
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 1 · 2020: 2 · 2019: 5 · 2018: 4 · 2017: 5 · 2016: 11 · 2015: 5 · 2014: 9 · 2013: 6 · 2012: 18
- FWCI
- 59.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- AIDS (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HIV-1 infection, protease inhibitors, peripheral insulin resistance, insulin sensitivity, oral glucose tolerance, impaired glucose tolerance, hyperlipidemia, serum lipids, diabetes mellitus, metabolic side effects, antiretroviral therapy
- MeSH terms
- Adult, Cholesterol, Female, Glucose Tolerance Test, Humans, Insulin Resistance, Male, Middle Aged, Triglycerides, HIV-1, HIV Infections, HIV Protease Inhibitors, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. https://app.cochat.ai/papers/10.1097/00002030-199815000-00001
- The paper
- Walli, R., Herfort, O., Michl, G. M., Demant, T., Jäger, H., Dieterle, C., Bogner, J. R., Landgraf, R., & Goebel, F. D. (1998). Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. https://doi.org/10.1097/00002030-199815000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.